Topic
Intermediate uveitis
About: Intermediate uveitis is a research topic. Over the lifetime, 789 publications have been published within this topic receiving 21610 citations. The topic is also known as: chronic cyclitis & peripheral uveoretinitis.
Papers published on a yearly basis
Papers
More filters
TL;DR: In this article, a process of standardizing the methods for reporting clinical data in the field of uveitis has been discussed, and the results used to develop a series of proposals to better standardize the use of these entities.
3,283 citations
678 citations
TL;DR: Uveitis may be induced by infection, autoimmune disease, trauma, or malignancy, and it is recommended that the different forms of uveitis should be classified according to their anatomical localisation.
Abstract: The inflammatory process of the uvea is called uveitis and may cause sight threatening damage to the eye. The aetiological factor in about 30% of the cases of uveitis is unknown. If established clinical entities without known cause, such as Fuchs' uveitis, are included, no aetiological agent or association with systemic disease can be identified in about 50% of cases.' Uveitis may be induced by infection, autoimmune disease, trauma, or malignancy. It is recommended that the different forms of uveitis should be classified according to their anatomical localisationanterior uveitis, intermediate uveitis, posterior uveitis, and panuveitis."3 The uvea plays an important role in the ocular immunological defence mechanisms. Immunologically speaking the eye has a deviant and privileged position because of the blood-retina barrier, absence of lymphatic drainage, and a special feature called the anterior chamber associated immune deviation (ACAID). These special defence mechanisms contribute to the preservation of vision.4 If these defence mechanisms fail, intraocular inflammation
525 citations
Duke University1, Moorfields Eye Hospital2, University of Bristol3, Paris Diderot University4, Johns Hopkins University5, Ghent University6, Medical University of Vienna7, University of Duisburg-Essen8, University of Texas Health Science Center at San Antonio9, AbbVie10, Portland VA Medical Center11, Oregon Health & Science University12
TL;DR: In this multinational phase 3 trial, adalimumab was found to be associated with a lower risk of uveitic flare or visual impairment and with more adverse events and serious adverse events than was placebo.
Abstract: BackgroundPatients with noninfectious uveitis are at risk for long-term complications of uncontrolled inflammation, as well as for the adverse effects of long-term glucocorticoid therapy. We conducted a trial to assess the efficacy and safety of adalimumab as a glucocorticoid-sparing agent for the treatment of noninfectious uveitis. MethodsThis multinational phase 3 trial involved adults who had active noninfectious intermediate uveitis, posterior uveitis, or panuveitis despite having received prednisone treatment for 2 or more weeks. Investigators and patients were unaware of the study-group assignments. Patients were randomly assigned in a 1:1 ratio to receive adalimumab (a loading dose of 80 mg followed by a dose of 40 mg every 2 weeks) or matched placebo. All patients received a mandatory prednisone burst followed by tapering of prednisone over the course of 15 weeks. The primary efficacy end point was the time to treatment failure occurring at or after week 6. Treatment failure was a multicomponent o...
405 citations
TL;DR: The appearance of new uveitic entities, such as the acute retinal necrosis syndrome, multifocal choroiditis and panuveitis, birdshot retinochoroidopathy, and acquired immunodeficiency syndrome-related uveitis, and the reemergence of the classic infectious causes of uveita, tuberculosis and syphilis, have changed the way the diagnosis and management of posterior andPanuveitis at the Massachusetts Eye and Ear Infirmary.
Abstract: Objective: To analyze the referral patterns and diagnosis of uveitis during the past decade in a large tertiary eye center. Design: The records of 1237 patients with uveitis referred to the Immunology Service of the Massachusetts Eye and Ear Infirmary from 1982 to 1992 were classified and analyzed. Data regarding sex, race, nationality, referral site, ages at presentation and onset of uveitis, ocular involvement, clinical characteristics, ocular condition, and systemic disease associations were obtained. Results: The mean age at onset of uveitis was 37.2 years; the male-to-female ratio was 1:1.4. Most patients were white (85.8%), born in the United States (83.1%), and referred from within New England (84.7%). Anterior uveitis was most common (51.6%), followed by posterior uveitis (19.4%), panuveitis (16.0%), and intermediate uveitis (13.0%). Chronic (58.3%), nongranulomatous (77.7%), and noninfectious (83.1%) were the most frequent types of uveitis. The most common entities included idiopathic (34.9%), seronegative spondyloarthropathies (10.4%), sarcoidosis (9.6%), juvenile rheumatoid arthritis (5.6%), systemic lupus erythematosus (4.8%), Behcet's disease (2.5%), and the acquired immunodeficiency syndrome (2.4%). Conclusion: The appearance of new uveitic entities, such as the acute retinal necrosis syndrome, multifocal choroiditis and panuveitis, birdshot retinochoroidopathy, and acquired immunodeficiency syndrome—related uveitis, and the reemergence of the classic infectious causes of uveitis, tuberculosis and syphilis, have changed the way we approach the diagnosis and management of posterior and panuveitis at the Massachusetts Eye and Ear Infirmary.
369 citations